We serve Chemical Name:kaempferoltetraacetate CAS:16274-11-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:kaempferoltetraacetate
CAS.NO:16274-11-6
Synonyms:4H-1-Benzopyran-4-one, 3,5,7-tris(acetyloxy)-2-[4-(acetyloxy)phenyl]-;2-(4-Acetoxyphenyl)-4-oxo-4H-chromene-3,5,7-triyl triacetate
Molecular Formula:C23H18O10
Molecular Weight:454.383
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:609.7±55.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.605
PSA:135.41000
Exact Mass:454.089996
LogP:1.16
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4H-1-Benzopyran-4-one, 3,5,7-tris(acetyloxy)-2-[4-(acetyloxy)phenyl]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-Acetoxyphenyl)-4-oxo-4H-chromene-3,5,7-triyl triacetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4H-1-Benzopyran-4-one, 3,5,7-tris(acetyloxy)-2-[4-(acetyloxy)phenyl]- Use and application,4H-1-Benzopyran-4-one, 3,5,7-tris(acetyloxy)-2-[4-(acetyloxy)phenyl]- technical grade,usp/ep/jp grade.
Related News: The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems. 5-(5-tert-Butyl-2-hydroxyphenyl)-4-chlor-1,2,3-dithiazolium-chlorid manufacturers During a conference call Thursday, Wall Street analysts piled into AstraZeneca’s China performance, pressing management on whether the company can sustain its double-digit sales growth in the country. N-(tert-butyl)-2-oxo-2-(o-tolyl)acetamide suppliers The most frequently reported adverse events for anifrolumab in the TULIP-1 and TULIP-2 trials were upper respiratory tract infection, bronchitis, infusion-related reactions and herpes zoster. 6β,16α-Dimethyl-pregnandiol-3β,5α-on-20-ethylenketal vendor & factory.
